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PERSPECTIvE
Mesenchymal stem cell therapy for 
retinal ganglion cell neuroprotection 
and axon regeneration
Retinal ganglion cells (RGCs) are responsible for propagat-
ing signals derived from visual stimuli in the eye to the 
brain, along their axons within the optic nerve to the 
superior colliculus, lateral geniculate nucleus and visu-
al cortex of the brain. Damage to the optic nerve either 
through trauma, such as head injury, or degenerative dis-
ease, such as glaucoma causes irreversible loss of function 
through degeneration of non-regenerating RGC axons 
and death of irreplaceable RGCs, ultimately leading to 
blindness (Berry et al., 2008). The degeneration of RGCs 
and their axons is due to the loss of the necessary source 
of retrogradely transported neurotrophic factors (NTFs) 
being hindered by axonal injury. NTFs are survival factors 
for neurons and play a pivotal part in axon regeneration. 
Stem cells particularly mesenchymal stem cells (MSCs) 
have been shown to possess a natural intrinsic capacity 
for paracrine support, releasing multiple signalling mol-
ecules including NTFs. By transplanting MSCs into the 
vitreous, they are positioned adjacent to the injured reti-
na to provide paracrine-mediated therapy for the retinal 
neuronal cells (Johnson et al., 2010a; Mead et al., 2013). 
Additionally, MSCs may be pre-differentiated into sup-
portive glial-like cells, such as Schwann cells, which could 
further increase their potential for paracrine support of 
injured neurons (Martens et al., 2013). Thus, MSCs have 
received considerable attention as a new cellular therapy 
for both traumatic and degenerative eye disease, acting as 
an alternative source of NTFs, protecting injured RGCs 
and promoting regeneration of their axons (Figure 1).
Bone marrow mesenchymal stem cells: Bone marrow 
mesenchymal stem cells (BMSCs) were the first MSCs 
to gather interest as a cellular therapy for ocular disease. 
Following transplantation into the vitreous of a rat model 
of glaucoma, BMSCs increased the number of surviving 
RGCs by 10–20% (Yu et al., 2006; Johnson et al., 2010a). 
In a model of traumatic optic nerve injury, BMSCs in-
creased the survival of RGCs by 15–20% 8–28 days after 
transection/crush of the optic nerve (Levkovitch-Verbin 
et al., 2010; Mead et al., 2013; Mesentier-Louro et al., 
2014) and increased the number of regenerating axons 
found at distances 100–1,200 µm distal to the lesion site 
by 2-fold compared to control animals receiving dead 
cells (Mead et al., 2013; Mesentier-Louro et al., 2014). In 
both models, the BMSCs survived but showed no sign 
of differentiating into neuronal or glial phenotypes, thus 
leading to the conclusion that the neuroprotective effects 
elicited were through paracrine-mediated effects, either 
direct signalling between the grafted stem cells and the in-
jured RGCs, or activation of retinal glia by the stem cells 
and glia-mediated neuroprotection/axogenesis.
dental pulp stem cells: We are interested in exploring the 
use of dental pulp stem cells (DPSCs) as an alternative 
source of stem cells for cellular therapy for the eye (Mead 
et al., 2013, 2014). DPSCs are neural crest-derived cells 
that can be isolated from adult teeth, an easily accessible 
source. Previous PCR-based gene expression studies sug-
gested that, like BMSCs, DPSCs secrete multiple NTFs. In 
our most recent study using an in vitro co-culture system 
using axotomised RGC, we compared human-derived 
DPSCs, BMSCs and adipose-derived mesenchymal stem 
cells (ADSCs) for their potential to protect and regenerate 
injured RGCs (Mead et al., 2014). Like BMSCs and DPSCs 
ADSCs secrete multiple different NTFs; however, their ef-
ficacy as a treatment for the eye is unknown. We cultured 
human-derived MSCs with injured rat retinal cells and 
assessed their neuroprotective and neuritogenic potential, 
and the role of specific NTFs including platelet-derived 
growth factor (PDGF) which was recognised as an im-
portant BMSC-derived factor for RGC neuroprotection 
(Johnson et al., 2013). In co-culture, we administered a 
variety of different Fc-fusion protein inhibitors to selec-
tively block particular receptors and assess the changes in 
neuroprotective and neuritogenic effects elicited by the 
MSCs. This study highlighted several important points: 
firstly, human-derived DPSCs were the most neuropro-
tective and neuritogenic, followed by BMSCs and ADSCs, 
respectively; secondly, a variety of NTFs were identified to 
play a significant role in the neuroprotection/neuritogen-
esis seen, including nerve growth factor (NGF), brain-de-
rived neurotrophic factor (BDNF) and neurotrophin-3 
(NT-3), as well as other NTFs such as glial cell line-de-
rived neurotrophic factor (GDNF), vascular endothelial 
growth factor (VEGF) and PDGF-AA/AB/BB; thirdly, 
the neuritogenic properties of the MSCs were strongly 
inhibited by Fc-TrkAr, suggesting NGF plays an import-
ant role in MSC-mediated axon regeneration. Finally, 
using Fc-PDGFA/Br inhibitors, our study underscored 
the important role of DPSC/MSC-derived PDGF-AA and 
PDGF-AB/BB in retinal neuroprotection confirming a 
previous study using BMSCs (Johnson et al., 2013). We 
substantiated our findings using ELISA analyses on con-
ditioned media from MSCs, confirming the secretion of 
NTFs by the MSCs with significantly higher quantities 
from DPSCs (Mead et al., 2014). We also performed a 
PCR array on the MSCs which indicated a diverse NTF 
profile of the three MSC populations. The distinct NTF 
profiles of DPSCs, BMSCs and ADSCs underlined the 
fact that the source of MSC is critical for determining 
the effectiveness of a planned cellular therapy. The PCR 
array data also revealed a previously unconsidered, and 
relatively unknown, factor, VGF-neuropeptide, which was 
expressed at considerably higher titres in DPSCs than 
BMSCs or ADSCs. At the time of our studies, very little 
was known about the neuroprotective/neuroregenerative 
properties of VGF. Thus, we ventured to investigate the 
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Figure 1 Schematic diagram demonstrating the effects of glaucoma 
and traumatic optic neuropathy on the eye and the potential of 
mesenchymal stem cells as a therapy.
MSCs to promote axon regeneration of RGCs after intra-
vitreal transplantation has recently been corroborated by 
another study (Mesentier-Louro et al., 2014).
The question is whether it is possible to further enhance 
the neurotrophic property of DPSCs/MSCs, and hence 
their therapeutic potential for nerve repair. In a recent 
study DPSCs that were differentiated into Schwann cells, 
a supportive glial cell of the peripheral nervous system, 
were shown to have significantly higher levels of secreted 
NTFs (Martens et al., 2013) compared to undifferenti-
ated cells. The effectiveness of differentiating stem cells 
into glia prior to treating the injured nervous system was 
evaluated by culturing the cells with injured dorsal root 
ganglion cells, a neuron found in the peripheral nervous 
system of the spinal cord. The authors demonstrated a 
significant increase in survival and neuritogenesis of dor-
sal root ganglion cells and also showed myelination of 
the growing neurites by DPSC-derived Schwann cells, in 
comparison to undifferentiated DPSCs. Although this was 
only an in vitro study in the peripheral nervous system, it 
is tempting to speculate that the elevated NTF secretion 
and subsequent neuroprotection of differentiated DP-
SC-derived Schwann cells may represent a more effica-
cious therapy for traumatic and degenerative eye disease 
and nerve repair.
Engraftment of stem cells in the retina: One interesting 
observation is the surprising ability for MSCs to survive 
in vivo when transplanted in the eye, with multiple stud-
ies detecting cells months after transplantation (Johnson 
et al., 2010a; Mead et al., 2013), which may be attributed 
to the immunoprivileged environment of the eye. How-
ever, despite this survival, MSCs were restricted to the vit-
reous, failing to engraft into the retina. A previous study 
identified that the barrier to engraftment is the activated 
glia which may prevent the injected stem cells migrating 
into the retina (Johnson et al., 2010b). It may be argued 
that the NTF-secreting MSCs would be more efficacious 
if in the same retinal microenvironment as the RGCs and 
even that the MSC survival following transplantation 
would be more pronounced if embedded in the cellular 
retina rather than clustered in the vitreous. Therefore, as 
well as enhancing the neurotrophic profile of MSCs by 
potentially differentiating them into glia, increasing the 
propensity for MSCs to engraft within the retina may 
possibly increase the neuroprotective and axogenic effects 
further. Further studies are warranted to clarify the most 
suitable stem cell injection site for retinal neural therapy. 
Conclusions: Although we have performed an in depth 
comparison of three common human-derived MSC types 
and identified DPSCs as the most efficacious cell type 
for RGC neuroprotection and axon regeneration, further 
studies are required to confirm the relative (pre)clinical ef-
ficacy of the different human-derived stem cells in vivo and 
therefore the most “advantageous” MSCs for ocular repair. 
Noteworthy, early clinical trials have recently started to test 
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effects of the recombinant VGF-neuropeptide on injured 
retinal cultures and elucidated that this new factor pre-
sented a potent neuroprotective effect (Mead et al., 2014). 
Considering this novel finding as well as the recently 
demonstrated importance of FGF-2 in BMSC-mediated 
neuroprotection of RGCs (Mesentier-Louro et al., 2014), 
it is very plausible that other neuroprotective/axogenic 
trophic molecules may be residing in the cocktail of the 
MSC secretome. Our study using primary human-derived 
MSCs corroborate our previous findings using rat pri-
mary cells that DPSCs were more potent in their in vitro 
RGC neuroprotection and RGC neuritogenesis which 
corresponded with their secretion of significantly higher 
levels of NGF, BDNF and NT-3 than BMSCs (Mead et al., 
2013). DPSCs were also more effective in an in vivo mod-
el of optic nerve/RGC injury whereby DPSCs promoted 
a significantly greater increase in RGC survival and a fur-
ther 2-fold increase in the number of regenerating axons 
found at distances 100–1,200 µm distal to the lesion site 
after intravitreal transplantation compared with BMSCs 
(Mead et al., 2013).This remarkable ability of DPSCs/
373
NEURAL REGENERATION RESEARCH 
March 2015, Volume 10, Issue 3 www.nrronline.org
the safety of BMSCs for retinal and optic nerve damage 
(www.clinicaltrials.gov/show/NCT01920867). Based on 
our recent findings, we propose DPSCs as a novel and 
advantageous MSC type for retinal neuroprotection and 
repair (Mead et al., 2013, 2014). 
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